Health Condition 1: L700- Acne vulgaris
Conditions
Interventions
Intervention1: TABLET ISOTRETINOIN: Dose:0.5mg/kg
Frequency: once a day
Route of administration: Oral
Total duration: 3 months
Control Intervention1: TABLET SPIRONOLACTONE: Dose:100mg
Frequency: once
Sponsors
Dr Shivani Tripathi
Eligibility
Inclusion criteria
Inclusion criteria: (1)All women of 25-45 years of age with acne of grade 2 and 3 (as per Pillsbury scale). (2)Women with facial acne involving lower third of face (mandibular line, perioral region, and side of the neck). (3)Cases willing to give informed consent.
Exclusion criteria
Exclusion criteria: (1)Patients below the age of 25 years. (2)Patients with grade 1 and 4 (as per Pillsbury scale) (3)Patients with predominately truncal acne. (4)Patients who have been on any topical or systemic treatment in last 1 month. (5)Patient who have undergone procedures such as any chemical peel, acne scar surgery in last 15 days prior to enrollment. (6)Pregnant and lactating women. (7)Patients planning to conceive. (8)Females on contraceptive or other medication that cause or worsen acne. (9)Patients on corticosteroids/antiepileptics/AKT/ART/antipsychotics. (10)Patient suffering from acne rosacea and other bacterial infections on face confounding the diagnosis of acne vulgaris. (11)Patient suffering from Androgen-secreting adrenal or ovarian tumour, Cushing?s syndrome, Congenital adrenal hyperplasia. (12)Patients who are immune-compromised or taking immunosuppressant. (13)Patients undergoing chemotherapy. (14)Patients with poor general health.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pillsbury grading scale, CADI, side effectsTimepoint: baseline, 2 week, 1 month, 2 month, 3 month | — |
Secondary
| Measure | Time frame |
|---|---|
| investigations: CBC, LFT, RFT, Hormonal profile, ultrasonography abdominal and pelvis, serum TSH, serum magnesiumTimepoint: baseline | — |
Countries
India
Contacts
Public ContactDr Shivani Tripathi
SBKS MI & RC
Outcome results
None listed